MVZ HPH Launches Cutting-Edge ctDNA Blood Test for Cancer Monitoring in Germany
In a significant advancement for cancer care in Europe, the MVZ HPH Institute for Pathology and Hematopathology GmbH has introduced the HPH MRD test, a groundbreaking blood test designed to detect circulating tumor DNA (ctDNA) and monitor minimal residual disease (MRD) in patients with solid tumors. This innovative testing method leverages the proven Haystack MRD® technology, developed by Haystack Oncology, a subsidiary of Quest Diagnostics®.
The introduction of the HPH MRD test marks a pivotal moment in cancer treatment, providing an essential tool in the fight against cancer. By utilizing advanced whole genome sequencing techniques, this test empowers physicians to detect extremely low concentrations of ctDNA. This level of sensitivity and specificity enables medical professionals to reliably identify residual or recurring cancer, opening the door to earlier and more informed treatment decisions.
Conducted in Hamburg, Germany, the HPH MRD testing grants local healthcare providers expedited access to next-generation MRD testing solutions, which were previously only available through international channels. "At HPH, we are committed to offering the highest quality diagnostic methodologies to facilitate personalized cancer care," said Prof. Markus Tiemann, managing director of MVZ HPH. He emphasized that this breakthrough enhances access to vital diagnostic tools, significantly reducing the time it takes for patients to receive test results.
Historically, monitoring cancer after initial treatments such as surgery and chemotherapy has been challenged by the potential presence of tiny tumor remnants that can lead to recurrence. Traditionally, imaging studies have struggled to detect these molecular signals effectively. However, the HPH MRD test significantly improves upon these limitations by identifying DNA fragments in the bloodstream that originate from tumors. This accurate detection informs clinicians about the most effective evidence-based treatment paths.
Dan Edelstein, Vice President and General Manager at Haystack Oncology, commented on the importance of this development. "Patients and physicians in Europe have lacked straightforward access to the most sensitive MRD technologies. Our licensing agreement with HPH is a critical step towards integrating next-generation MRD testing into routine care beyond the United States."
The MVZ HPH Institute has been operational since 2004, specializing in the diagnosis of solid tumors and hematopathological conditions. With a deep commitment to applied molecular pathology, the institute employs a diverse range of diagnostic techniques, including conventional histology, immunohistochemistry, and next-generation sequencing, ensuring patients receive precise diagnoses that guide treatment decisions.
The HPH MRD test is not just a progression in technology but represents a shift towards a more personalized approach in oncology. As healthcare continues to evolve, embracing tools that allow for timely and nuanced insights into cancer progression will be critical in improving patient outcomes.
For more details about the HPH MRD test and the services offered by MVZ HPH Institute, visit haematopathologie-hamburg.de or reach out via email to [email protected].
The introduction of the HPH MRD test marks a pivotal moment in cancer treatment, providing an essential tool in the fight against cancer. By utilizing advanced whole genome sequencing techniques, this test empowers physicians to detect extremely low concentrations of ctDNA. This level of sensitivity and specificity enables medical professionals to reliably identify residual or recurring cancer, opening the door to earlier and more informed treatment decisions.
Conducted in Hamburg, Germany, the HPH MRD testing grants local healthcare providers expedited access to next-generation MRD testing solutions, which were previously only available through international channels. "At HPH, we are committed to offering the highest quality diagnostic methodologies to facilitate personalized cancer care," said Prof. Markus Tiemann, managing director of MVZ HPH. He emphasized that this breakthrough enhances access to vital diagnostic tools, significantly reducing the time it takes for patients to receive test results.
Historically, monitoring cancer after initial treatments such as surgery and chemotherapy has been challenged by the potential presence of tiny tumor remnants that can lead to recurrence. Traditionally, imaging studies have struggled to detect these molecular signals effectively. However, the HPH MRD test significantly improves upon these limitations by identifying DNA fragments in the bloodstream that originate from tumors. This accurate detection informs clinicians about the most effective evidence-based treatment paths.
Dan Edelstein, Vice President and General Manager at Haystack Oncology, commented on the importance of this development. "Patients and physicians in Europe have lacked straightforward access to the most sensitive MRD technologies. Our licensing agreement with HPH is a critical step towards integrating next-generation MRD testing into routine care beyond the United States."
The MVZ HPH Institute has been operational since 2004, specializing in the diagnosis of solid tumors and hematopathological conditions. With a deep commitment to applied molecular pathology, the institute employs a diverse range of diagnostic techniques, including conventional histology, immunohistochemistry, and next-generation sequencing, ensuring patients receive precise diagnoses that guide treatment decisions.
The HPH MRD test is not just a progression in technology but represents a shift towards a more personalized approach in oncology. As healthcare continues to evolve, embracing tools that allow for timely and nuanced insights into cancer progression will be critical in improving patient outcomes.
For more details about the HPH MRD test and the services offered by MVZ HPH Institute, visit haematopathologie-hamburg.de or reach out via email to [email protected].
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.